Amneal Pharmaceuticals (AMRX) Other financing activities (2017 - 2026)

Amneal Pharmaceuticals has reported Other financing activities for 10 years, with the latest figure at $2.0 million in Q1 2026.

• On a quarterly basis, Other financing activities rose 2772.46% year-over-year to $2.0 million in Q1 2026; TTM through Jun 2026 was $2.2 million, a 12.57% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, up 69.84% from the prior year.
• Other financing activities was $2.0 million for Q1 2026 at Amneal Pharmaceuticals, up from -$73.0 million in the prior quarter.
• The five-year high for Other financing activities was $73.2 million in Q3 2025, with the low at -$73.0 million in Q4 2025.
• Average Other financing activities over 5 years is $413933.3, with a median of $151000.0 recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Other financing activities soared 30120.0% in 2022, then sank 48452.98% in 2025.
• Over 5 years, Other financing activities stood at -$1.0 million in 2022, then soared by 90.91% to -$91000.0 in 2023, then jumped by 265.93% to $151000.0 in 2024, then tumbled by 48452.98% to -$73.0 million in 2025, then jumped by 102.71% to $2.0 million in 2026.
• The last three Other financing activities figures came in at $2.0 million (Q1 2026), -$73.0 million (Q4 2025), and $73.2 million (Q3 2025), per Business Quant data.